

RNS Number : 4709B
EKF Diagnostics Holdings PLC
04 March 2014

**EKF Diagnostics Holdings plc
("EKF" or the "Company")**

Transfer of production

EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, announces that the Company proposes to transfer all production of Quo-Test and Quo-Lab instruments and reagents cartridges from the Quotient facilities in Hersham, near Walton-on-Thames, to the Company's manufacturing site in Barleben, Germany.

In the recent final results statement the Company announced that it has invested in an automated manufacturing line for Quo-Lab reagent cartridges, which is expected to become operational shortly in EKF's own 96,000 square feet facility in Barleben. The proposed transfer of production of Quotient products to the Barleben facility will allow the group to reduce the size of its manufacturing footprint and therefore reduce its manufacturing costs.

EKF Diagnostics Holdings plc

David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, Finance Director

Tel: 029 2071 0570

Mob: 07740 084 452
Mob: 07788 420 859
Mob: 07710 989 255

Canaccord Genuity Limited

Lucy Tilley / Henry Fitzgerald-O'Connor

Tel: 020 7523 8000

Walbrook PR Limited

Paul McManus

Paul Cornelius

Tel: 020 7933 8780

Mob: 07980 541 893 or

paul.mcmanus@walbrookpr.com

Mob: 07866 384 707 or paul.cornelius@walbrookir.com

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRAQKQDDDBKDQNK admin Transfer of production 21519233 A Tue, 03/04/2014 - 11:16 Company
Announcement - General EKF